Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
Go back to Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 17.85 +0.13 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.72 | 52 Week High | $19.75 | |||
| Open | $17.74 | 52 Week Low | $4.26 | |||
| Day High | $17.87 | P/E | N/A | |||
| Day Low | $17.31 | EPS | $0.00 | |||
| Volume | 13,060,178 | |||||
